breast cancer

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) have collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader.  The estrogen receptor is a well-known disease driver in...

Biocept Inc (NASDAQ: BIOC) received a favorable final Local Coverage Determination expanding Medicare coverage for the use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells (CTCs).  Reimbursement decision expands access to testing...

Merck & Co Inc (NYSE: MRK) has announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522 trial of Keytruda (pembrolizumab) in breast cancer.  The trial investigated neoadjuvant (delivered before the primary treatment)...

BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ: INCY).  The Phase 1/2a combination study will evaluate BriaCell's lead candidate, Bria-IMT, with Incyte's...

Atossa Therapeutics Inc (NASDAQ: ATOS) shares are trading higher Tuesday after retail traders were able to push the stock higher. The stock was trading on above-average volume Tuesday and was trending on social media sites throughout the day such as StockTwits. Atossa Therapeutics was up 13.42...

Health Canada has approved Puma Biotechnology Inc's (NASDAQ: PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. Knight...

Athenex Inc (NASDAQ: ATNX) held a Type A meeting with the FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter (CRL) regarding application for oral paclitaxel plus encequidar to treat metastatic breast cancer. At the meeting,...

BriaCell Therapeutics Corp (NASDAQ: BCTX) has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The company anticipates commencing clinical trials...

Tyme Technologies Inc (NASDAQ: TYME) announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3 of 2021. The investigator-initiated prospective open-label Phase 2 trial will evaluate the efficacy and safety of SM-88 for metastatic...

Atossa Therapeutics Inc (NASDAQ: ATOS) has announced final data from its Phase 2 study of oral Endoxifen administered between the diagnosis of breast cancer and surgery. The study enrolled seven newly-diagnosed patients with ER+ and human epidermal growth factor receptor 2 negative...

Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent, in heavily pre-treated breast cancer patients. Data will be presented at the American Society of Clinical Oncology 2021...

Greenwich LifeSciences Inc (NASDAQ: GLSI) presented five-year data from Phase 2 breast cancer clinical trial evaluating GP2 immunotherapy in patients who have previously undergone surgery. Data were presented at the 2021 American Society of Clinical Oncology Annual Meeting. Final...

Gilead Sciences Inc (NASDAQ: GILD) has announced new data from the Phase 3 ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC). Data were presented at the American Society of Clinical Oncology Annual...

Sanofi SA (NASDAQ: SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast cancer. The Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC), and the Alliance Foundation...

AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating Lynparza (olaparib) in a subset of early breast cancer patients. Results will be presented at the 2021 American Society...